Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria
Journal Title:
Expert Review of Clinical Pharmacology
Original Publication Date:
Sep 2024
Bone Marrow Disease(s):
Crovalimab, a novel C5 inhibitor, allows for low-volume, every-4- week, subcutaneous self-administration. COMMODORE 1 (NCT04432584) is a phase 3, global, randomized trial evaluating crovalimab versus eculizumab in C5 inhibitor-experienced patients with